Alosetron for severe diarrhea-predominant irritable bowel syndrome: Safety and efficacy in perspective

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 1, 2010, Pages 13-29

  Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5 HT3 antagonist; Alosetron; Irritable bowel syndrome; Lotronex ; Post marketing surveillance; Prescription program; Risk management program; Serotonin antagonist

Indexed keywords

ALOSETRON; ALPRAZOLAM; ANTIBIOTIC AGENT; CYTOCHROME P450 1A2 INHIBITOR; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; ETHINYLESTRADIOL; FLUOXETINE; FLUVOXAMINE; LEVONORGESTREL; LOPERAMIDE; PLACEBO; PROBIOTIC AGENT; SPASMOLYTIC AGENT; THEOPHYLLINE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECALL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; IRRITABLE COLON; ISCHEMIC COLITIS; PATHOGENESIS; PATIENT SATISFACTION; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE;

CARBOLINES; COLITIS, ISCHEMIC; CONSTIPATION; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; PATIENT SATISFACTION; PRODUCT SURVEILLANCE, POSTMARKETING; QUALITY OF LIFE; SAFETY-BASED DRUG WITHDRAWALS; SEROTONIN ANTAGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77951677635     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.72     Document Type: Review

References (108)

1. Mertz HR. Irritable bowel syndrome. N. Engl. J. Med. 349(22), 2136-2146 (2003).
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130(5), 1480-1491 (2006).
3. Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment. Pharmacol. Ther. 13(Suppl. 2), 3-14 (1999)
4. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am. J. Gastroenterol. 104(Suppl. 1), S1-S35 (2009).
5. Mayer EA. Clinical practice. Irritable bowel syndrome. N. Engl. J. Med. 358(16), 1692-1699 (2008).
6. Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am. J. Gastroenterol. 97(8), 1910-1915 (2002)
7. Systematic review on the management of irritable bowel syndrome in the European Union. Eur. J. Gastroenterol. Hepatol. 19(Suppl. 1), S11-S37 (2007).
8. Andrews EB, Eaton SC, Hollis KA et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment. Pharmacol. Ther. 22(10), 935-942 (2005).
9. Drossman DA, Li Z, Andruzzi E et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci. 38(9), 1569-1580 (1993).
10. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment. Pharmacol. Ther. 21(11), 1365-1375 (2005).
11. Drossman DA, Morris CB, Hu Y et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defning an alternator. Gastroenterology 128(3), 580-589 (2005).
12. Ersryd A, Posserud I, Abrahamsson H, Simren M. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. Aliment. Pharmacol. Ther. 26(6), 953-961 (2007).
13. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment. Pharmacol. Ther. 16(6), 1171-1185 (2002).
14. Drossman DA, Chang L, Schneck S, Blackman C, Norton WF, Norton NJ. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig. Dis. Sci. 54(7), 1532-1541 (2009).
15. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin. Gastroenterol. Hepatol. 3(8), 717-725 (2005). (Pubitemid 41116722)
16. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119(3), 654-660 (2000).
17. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 126(7), 1665-1673 (2004).
18. American Gastroenterological Association. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 123(6), 2105-2107 (2002).
19. Posserud I, Ersryd A, Simren M. Functional fndings in irritable bowel syndrome. World J. Gastroenterol. 12(18), 2830-2838 (2006).
20. Choung RS, Locke GR 3rd, Zinsmeister AR, Schleck CD, Talley NJ. Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am. J. Gastroenterol. 104(7), 1772-1779 (2009).
21. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment. Pharmacol. Ther. 11(1), 3-15 (1997).
22. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 123(6), 2108-2131 (2002). (Pubitemid 35408332)
23. Tornblom H, Abrahamsson H, Barbara G et al. Infammation as a cause of functional bowel disorders. Scand. J. Gastroenterol. 40(10), 1140-1148 (2005).
24. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 136(6), 1979-1988 (2009).
25. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffn cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125(6), 1651-1659 (2003).
26. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade infammatory bowel disease? Gastroenterol. Clin. North Am. 34(2), 235-245, vi-vii (2005).
27. Sidhu R, Drew K, McAlindon ME, Lobo AJ, Sanders DS. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and infammatory bowel disease (IBD): a shared model for pathogenesis? Infamm. Bowel Dis. DOI: 10.1002/ibd.20982 (2009) (Epub ahead of print).
28. Santos J, Alonso C, Vicario M, Ramos L, Lobo B, Malagelada JR. Neuropharmacology of stress-induced mucosal infammation: implications for infammatory bowel disease and irritable bowel syndrome. Curr. Mol. Med. 8(4), 258-273 (2008).
29. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and infammatory bowel disease-irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 7(1), 48-53 (2009).
30. Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment. Pharmacol. Ther. 13(Suppl. 2), 15-30 (1999).
31. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 61(3), 317-332 (2001).
32. Gershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev. Gastroenterol. Disord. 3(Suppl. 2), S25-S34 (2003).
33. Bulbring E, Crema A. The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosa. J. Physiol. 146(1), 18-28 (1959).
34. 4 5-hydroxytryptamine from the ferret and rat intestine. Res. Commun. Mol. Pathol. Pharmacol. 89(2), 131-142 (1995).
35. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 12(9), 849-855 (1998).
36. Bardhan KD, Bodemar G, Geldof H et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the effcacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 14(1), 23-34 (2000).
37. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol. Ther. 14(6), 775-782 (2000).
38. Miller JL. Alosetron approved for treatment of irritable bowel syndrome. Am. J. Health Syst. Pharm. 57(6), 519 (2000).
39. Olden K, DeGarmo RG, Jhingran P et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 97(12), 3139-3146 (2002).
40. Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am. J. Gastroenterol. 101(5), 1069-1079 (2006).
41. Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet 357(9268), 1544-1545 (2001).
42. McCarthy M. FDA recommends bringing controversial IBS drug back. Lancet 359(9316), 1491-1492 (2002).
43. Andresen V, Hollerbach S Reassessing the Benefts and Risks of Alosetron: What Is Its Place in the Treatment of Irritable Bowel Syndrome? Drug Saf. 27(5), 283-292 (2004).
44. Ameen VZ, Tong K, Pan H. The Risk Management Program (RiskMAP) is effective in mitigating serious outcomes of ischemic colitis and complications of constipation with marketed use of alosetron since reintroduction. Presented at: 2008 Annual Meeting of the American College of Gastroenterology. Orlando, FL, USA, 3-8 October 2008 (Abstract P693).
45. ® (alosetron hydrochloride) tablets (package insert). Prometheus Laboratories Inc., San Diego, CA, USA (2008).
46. Karwoski CB. Practical experience with risk management plans in the US. Presented at: 42nd Annual Drug Information Association Meeting. Philadelphia, PA, USA, 18-22 June (2006).
47. Koch KM, Corrigan BW, Manzo J et al. Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and infuence of demographic factors. Aliment. Pharmacol. Ther. 20(2), 223-230 (2004).
48. Koch K, Campanella C, Baidoo CA, Manzo JA, Ameen VZ, Kersey KE. Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex). Dig. Dis. Sci. 49(7-8), 1244-1249 (2004).
49. Koch KM, Ricci BM, Hedayetullah NS, Jewell D, Kersey KE. Effect of alosetron on theophylline pharmacokinetics. Br. J. Clin. Pharmacol. 52(5), 596-600 (2001).
50. D'Souza DL, Dimmitt DC, Robbins DK, Nezamis J, Simms L, Koch KM. Effect of alosetron on the pharmacokinetics of fuoxetine. J. Clin. Pharmacol. 41(4), 455-458 (2001).
51. D'Souza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM. Effect of alosetron on the pharmacokinetics of alprazolam. J. Clin. Pharmacol. 41(4), 452-454 (2001).
52. Gunput MD. Review article: clinical pharmacology of alosetron. Aliment. Pharmacol. Ther. 13(Suppl. 2), 70-76 (1999).
53. 3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment. Pharmacol. Ther. 11(6), 1109-1114 (1997).
54. Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 132(7), 2287-2290 (2007).
55. Hasler WL, Schoenfeld P Safety Profle of Tegaserod, A 5-HT4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome. Drug Saf. 27(9), 619-631 (2004).
56. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Effcacy of 5-HT antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol. 104(7), 1831-1843 (2009).
57. Glaxo Wellcome withdraws irritable bowel syndrome medication FDA Consum. 35(1), 3 (2001).
58. Krause R, Ameen V, Gordon SH et al. A randomized, double-blind, placebo-controlled study to assess effcacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am. J. Gastroenterol. 102(8), 1709-1719 (2007).
59. Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin. Gastroenterol. Hepatol. 2(8), 675-682 (2004).
60. Lembo T, Wright RA, Bagby B et al Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 96(9), 2662-2670 (2001).
61. Chey WD, Chey WY, Heath AT et al Long-term safety and effcacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 99(11), 2195-2203 (2004).
62. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Effcacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355(9209), 1035-1040 (2000).
63. Camilleri M, Chey W Y, Mayer EA et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch. Intern. Med. 161(14), 1733-1740 (2001).
64. 3 receptor antagonist. Aliment. Pharmacol. Ther. 13(9), 1149-1159 (1999).
65. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 11(3), 547-552 (1997).
66. Watson ME, Lacey L, Kong S et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 96(2), 455-459 (2001).
67. Wolfe SG, Chey WY, Washington MK et al. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am. J. Gastroenterol. 96(3), 803-811 (2001).
68. Lembo A, Weber HC, Farraye FA. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder. Drugs 63(18), 1895-1905 (2003).
69. Gallo-Torres H, Brinker A, Avigan M. Alosetron: ischemic colitis and serious complications of constipation. Am. J. Gastroenterol. 101(5), 1080-1083 (2006).
70. American Gastroenterological Association Medical Position Statement: guidelines on intestinal ischemia. Gastroenterology 118(5), 951-953 (2000).
71. Greenwald DA, Brandt LJ. Colonic ischemia. J. Clin. Gastroenterol. 27(2), 122-128 (1998).
72. Ringel Y, Wilson J, D'Agostino R, Henson L, Lewis J. Development and validation of an ischemic colitis clinical diagnostic assessment instrument. Gastroenterology 128(4 Suppl. 2), A467 (2005) (Abstract 1152).
73. Camilleri M Is There An Experimental Basis for the Development of Ischaemic Colitis As A Result of 5-HT Antagonist Treatment? Neurogastroenterol. Motil. 19(2), 77-84 (2007).
74. Grundy D, McLean P, Stead R. Impact of 5-HT receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat. Neurogastroenterol. Motil. 19(7), 607-616 (2007).
75. Friedel D, Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology 120(2), 557-560 (2001).
76. Hervé S, Beaugerie L, Bouhnik Y et al Irritable bowel syndrome is more frequent in patients hospitalized for ischaemic colitis: results of a case-control study. Neurogastroenterol. Motil. 21(11), 1170-e102 (2009).
77. Cole JA, Cook SF, Sands BE, Ajene AN, Miller DP, Walker AM. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am. J. Gastroenterol. 99(3), 486-491 (2004).
78. Walker AM, Bohn RL, Cali C, Cook SF, Ajene AN, Sands BE. Risk factors for colon ischemia. Am. J. Gastroenterol. 99(7), 1333-1337 (2004).
79. Chang L, Kahler KH, Sarawate C, Quimbo R, Kralstein J. Assessment of potential risk factors associated with ischaemic colitis. Neurogastroenterol. Motil. 20(1), 36-42 (2008).
80. Suh DC, Kahler KH, Choi IS, Shin H, Kralstein J, Shetzline M. Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis. Aliment. Pharmacol. Ther. 25(6), 681-692 (2007).
81. Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am. J. Gastroenterol. 98(5), 1117-1122 (2003).
82. Camilleri M, Mayer EA. Developing irritable bowel syndrome guidelines through meta-analyses: does the emperor really have new clothes? Gastroenterology 137(3), 766-769 (2009).
83. Miller D, Bennett L, Hollis K, Tennis P, Cook S, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment. Pharmacol. Ther. 24(5), 869-878 (2006).
84. Traynor K. Alosetron use drops dramatically with risk management. Am. J. Health Syst. Pharm. 61(12), 1210-1212 (2004).
85. Tuncer C, Cindoruk M, Dursun A, Karakan T. Prevalence of microscopic colitis in patients with symptoms suggesting irritable bowel syndrome. Acta Gastroenterol. Belg. 66(2), 133-136 (2003).
86. Murray JA, Van Dyke C, Plevak MF, Dierkhising RA, Zinsmeister AR, Melton LJ 3rd. Trends in the identifcation and clinical features of celiac disease in a North American community, 1950-2001. Clin. Gastroenterol. Hepatol. 1(1), 19-27 (2003).
87. Kalliomaki MA. Food allergy and irritable bowel syndrome. Curr. Opin. Gastroenterol. 21(6), 708-711 (2005).
88. Lacy BE. Evolving concepts in irritable bowel syndrome. Suppl. Gastroenterol. Endosc. News 6, 51-64 (2008).
89. Lackner JM, Mesmer C, Morley S, Dowzer C, Hamilton S. Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J. Consult. Clin. Psychol. 72(6), 1100-1113 (2004).
90. Schiller LR, Johnson DA. Balancing drug risk and beneft: toward refning the process of FDA decisions affecting patient care. Am. J. Gastroenterol. 103(4), 815-819 (2008).
91. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 98(1), 175-179 (2003).
92. Fontana RJ, McCashland TM, Benner KG et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl. Surg. 5(6), 480-484 (1999).
93. Lazarczyk DA, Goldstein NS, Gordon SC. Trovafoxacin hepatotoxicity. Dig. Dis. Sci. 46(4), 925-926 (2001).
94. Feld AD. Legal risks in treating irritable bowel syndrome. Rev. Gastroenterol. Disord. 3(Suppl. 3), S25-S31 (2003).
95. Charapata C, Mertz H. Physician knowledge of Rome symptom criteria for irritable bowel syndrome is poor among non-gastroenterologists. Neurogastroenterol. Motil. 18(3), 211-216 (2006).
96. Lacy BE, Rosemore J, Robertson D, Corbin DA, Grau M, Crowell MD. Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand. J. Gastroenterol. 41(8), 892-902 (2006).
97. Adeniji OA, Barnett CB, Di Palma JA. Durability of the diagnosis of irritable bowel syndrome based on clinical criteria. Dig. Dis. Sci. 49(4), 572-574 (2004).
98. Spiegel BM, DeRosa VP, Gralnek IM, Wang V, Dulai GS. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 126(7), 1721-1732 (2004).
99. Williams RE, Black CL, Kim HY et al. Stability of irritable bowel syndrome using a Rome II-based classifcation. Aliment. Pharmacol. Ther. 23(1), 197-205 (2006).
100. Halder SL, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 133(3), 799-807 (2007).
101. Lacy BE, Weiser K, Noddin L et al. Irritable bowel syndrome: patients' attitudes, concerns and level of knowledge. Aliment. Pharmacol. Ther. 25(11), 1329-1341 (2007).
102. Mangel AW. Personal view: adequate relief as a primary endpoint in irritable bowel syndrome. Aliment. Pharmacol. Ther. 23(7), 879-881 (2006).
103. Kaptchuk TJ, Kelley JM, Conboy LA et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336(7651), 999-1003 (2008).
104. Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment. Pharmacol. Ther. 29(8), 834-842 (2009).
105. Enrolling in the Prescribing Program for Lotronex (PPL) www.lotronex.com/Physicians/Prescribing/Enrollment.asp (Accessed 10 July, 2009)
106. Prometheus Laboratories. Prescribing program for Lotronex physician enrollment form www.lotronex.com/download/physician- enrollment.pdf (Accessed 10 July, 2009)
107. Important changes regarding Propulsid (cisapride) Tablets and Suspension. 12 April 2000 www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a-tab4d.htm (Accessed 10 July, 2009)
108. Zelnorm (tegaserod maleate) information 4/2/2008 www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationfor Patientsand Providers/ucm103223. htm (Accessed 10 July, 2009)